APTITUDE HEALTH®

EPICS

Conference Coverage: ASCO 2023 – Focus on Lung Cancer

Full Report

June 16, 2023

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
June 16, 2023



DISEASE STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in lung cancer
- > 5 from US
- > 3 from Europe

LUNG CANCER-SPECIFIC DISCUSSIONS on therapeutic advances and their application in clinical decision-making

Panel Consisting of 5 US and 3 European Lung Cancer Experts

EPICS

Marina Chiara Garassino, MD
University of Chicago

Lynette Sholl, MD
Harvard Medical School

Roy Herbst, MD, PhD
Yale Cancer Center

CHAIR:
Corey J. Langer, MD, FACP
University of Pennsylvania

Benjamin Besse, MD, PhD
Institute Gustave Roussy

Solange Peters, MD, PhD
University Hospital of Lausanne

Mark Socinski, MD
AdventHealth Cancer Institute

Enriqueta Felip, MD, PhD
Vall d'Hebron University Hospital

Meeting Agenda

EPICS

Time (EDT)	Topic	Speaker/Moderator
12.00 PM – 12.05 PM	**Welcome and Introductions**	Corey J. Langer, MD, FACP
12.05 PM – 12.20 PM	**Immunotherapy in Resectable NSCLC**	Marina Chiara Garassino, MD
12.20 PM – 12.50 PM	Discussion	All faculty
12.50 PM – 1.00 PM	**Updates in Stage IV NSCLC**	Solange Peters, MD, PhD
1.00 PM – 1.20 PM	Discussion	All faculty
1.20 PM – 1.30 PM	***EGFR* Mutations**	Roy Herbst, MD, PhD
1.30 PM – 1.45 PM	Discussion	All faculty
1.45 PM – 1.55 PM	**Break**	
1.55 PM – 2.10 PM	**Other Oncogenic Drivers**	Enriqueta Felip, MD, PhD; Mark Socinski, MD
2.10 PM – 2.30 PM	Discussion	All faculty
2.30 PM – 2.40 PM	**Small Cell Lung Cancer**	Benjamin Besse, MD, PhD
2.40 PM – 2.55 PM	Discussion	All faculty
2.55 PM – 3.00 PM	**Wrap-up Comments and Adjourn**	Corey J. Langer, MD, FACP

APTITUDE HEALTH®

EPICS

Congress Highlights

Immunotherapy in Resectable NSCLC

AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

Heymach JV, et al. AACR 2023, Abstract CT005

EPICS

STUDY POPULATION

> Resectable, stage IIA–IIIB (N2) NSCLC by AJCC 8th edition

EVENT-FREE SURVIVAL

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

Wakelee HA, et al. ASCO 2023, Abstract LBA100

EPICS

STUDY POPULATION

> Resectable, stage II–IIIB (N2) NSCLC by AJCC 8th edition

EVENT-FREE SURVIVAL

Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study

Lu S et al. ASCO 2023, Abstract 8501

EPICS

STUDY POPULATION

> Resectable, stage II–III NSCLC

EVENT-FREE SURVIVAL

APTITUDE HEALTH®

EPICS

Key Insights

Immunotherapy in Resectable NSCLC

Immunotherapy in Resectable NSCLC (1/2)

EPICS

The experts view perioperative immunotherapy (ie, immunotherapy both pre- and postsurgery) positively, although they recognize that

Immunotherapy in Resectable NSCLC (2/2)

EPICS

For patients who achieve a pCR after the neoadjuvant component in a perioperative approach, expert opinion is that there are

APTITUDE HEALTH®

EPICS

Congress Highlights

Updates in Stage IV NSCLC

Updates on Abstract 397600: ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC)

Johnson ML, et al. ASCO 2023, Abstract 397600

EPICS

STUDY POPULATION

> Treatment-naive, metastatic NSCLC; PD-L1 ≥50%

PROGRESSION-FREE SURVIVAL

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01

Rohrberg KS et al. ASCO 2023, Abstract 9050

EPICS

STUDY POPULATION

> Stage III unresectable/IV NSCLC; PD-L1 ≥1%

BEST PERCENTAGE CHANGE IN LESION SIZE

Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy

He K, et al. ASCO 2023, Abstract 9024

EPICS

STUDY POPULATION

> Pts with metastatic NSCLC, no targetable mutations; progressed

BEST PERCENTAGE CHANGE IN LESION SIZE

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC)

Goto Y et al. ASCO 2023, Abstract 9004

EPICS

STUDY POPULATION

> Pts with advanced/metastatic NSCLC and ≤2 prior therapies

BEST PERCENTAGE TUMOR CHANGE FROM BASELINE

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study

Leal T, et al. ASCO 2023, Abstract LBA9005

EPICS

STUDY POPULATION

> Pts with metastatic NSCLC progressing on or after platinum-

OS IN PATIENTS RECEIVING IMMUNOTHERAPY + TTF

APTITUDE HEALTH®

EPICS

Key Insights

Updates in Stage IV NSCLC

Updates in Stage IV NSCLC (1/2)

EPICS

The experts believe the phase III LUNAR trial evaluating Tumor Treating Fields (TTF) therapy showed a positive OS signal in

Updates in Stage IV NSCLC (2/2)

EPICS

Expert opinion is that TIGIT is a valid therapeutic target in NSCLC, but clinical trials with different anti-TIGIT agents so far have yielded

APTITUDE HEALTH®

EPICS

Congress Highlights

EGFR Mutations

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)

Herbst RS, et al. ASCO 2023, Abstract LBA3

EPICS

STUDY POPULATION

> Pts with completely resected, stage IB–IIIA NSCLC and an *EGFR* exon 19 deletion or L858R mutation

OVERALL SURVIVAL (STAGE II/IIIA)

- Adjuvant osimertinib demonstrated a statistically and clinically significant improvement in OS vs placebo in the

BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced *EGFR*-mutant (*EGFRm*) NSCLC in the phase 1/2 SYMPHONY study

Elamin YY, et al. ASCO 2023, Abstract 9011

EPICS

STUDY POPULATION

> Pts with metastatic, *EGFR*-mutated NSCLC and at least 1 T790M-targeting EGFR TKI; PD on osimertinib as last therapy

TUMOR RESPONSE: BLU-945 + OSIMERTINIB

Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (*EGFR*m$^+$) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis

Wu YL, et al. ASCO 2023, Abstract 9001

EPICS

STUDY POPULATION

> Pts with advanced *EGFR*-mutated NSCLC (exon 19 del or L858R)

PROGRESSION-FREE SURVIVAL

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study

Zhang L, et al. ASCO 2023, Abstract 3001

EPICS

STUDY POPULATION

> Pts with advanced solid tumors; experienced failure of standard

TUMOR RESPONSE IN *EGFR*-MUTATED NSCLC

SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study

Fang W, et al. ASCO 2023, Abstract 9114

EPICS

STUDY POPULATION

> Pts with advanced solid tumors

TUMOR RESPONSE

Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results

Wang M, et al. ASCO 2023, Abstract 9002

EPICS

STUDY POPULATION

> Advanced NSCLC with an *EGFR* exon 20 insertion mutation and 1–3 prior lines of therapy, including platinum-based chemotherapy

ANTITUMOR ACTIVITY BY MUTATION SUBTYPE

APTITUDE HEALTH®

EPICS

Key Insights

EGFR Mutations

EGFR Mutations (1/2)

EPICS

Regarding molecular testing of patients who progress on osimertinib, the pathology expert mentioned that their institution uses a

EGFR Mutations (2/2)

EPICS

Regarding efforts to improve on first-line osimertinib monotherapy in metastatic disease, such as combination regimens or new

APTITUDE HEALTH®

EPICS

Congress Highlights

Other Oncogenic Drivers

Adagrasib (MRTX849) in patients with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency

Janne PA, et al. ELCC 2023, Abstract 8MO

EPICS

STUDY POPULATION

- Pts with advanced NSCLC and a *KRAS* G12C mutation
- Prior immunotherapy and chemotherapy

PROGRESSION-FREE SURVIVAL BY MAFC

The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L)

Sakata S, et al. ASCO 2023, Abstract 9006

EPICS

STUDY POPULATION

> Pts with advanced NSCLC and a *KRAS* G12C mutation

TUMOR RESPONSE

KontRASt-01 update: Safety and efficacy of JDQ443 in *KRAS G12C*-mutated solid tumors including non-small cell lung cancer (NSCLC)

Cassier PA, et al. ASCO 2023, Abstract 9007

EPICS

STUDY POPULATION

> Pts with solid tumors and a *KRAS* G12C mutation

TUMOR RESPONSE



Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated *KRAS* G12C-mutated advanced non-small cell lung cancer (NSCLC)

Skoulidis F, et al. ASCO 2023, Abstract 9008

EPICS

STUDY POPULATION

> Pts with advanced NSCLC and a *KRAS* G12C mutation

PROGRESSION-FREE SURVIVAL BY COALTERATION

Intracranial efficacy of sotorasib versus docetaxel in pretreated *KRAS* G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)

Dingemans AMC, et al. ASCO 2023, Abstract LBA9016

EPICS

STUDY POPULATION

> Pts with advanced NSCLC and a *KRAS* G12C mutation

CNS PROGRESSION-FREE SURVIVAL

Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with *BRAF*V600E-mutant (*BRAF*^{V600E}) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study

Riely GJ, et al. ASCO 2023, Abstract 9018

EPICS

STUDY POPULATION

> Pts with advanced NSCLC and a *BRAF* V600E mutation

TUMOR RESPONSE

FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors

Ma Y, et al. ASCO 2023, Abstract 9015

EPICS

STUDY POPULATION

> Pts with solid tumors and an *ALK* or *ROS1* fusion

TUMOR RESPONSE, SECOND-GEN ALK TKI RESISTANT

APTITUDE HEALTH®

EPICS

Key Insights

Other Oncogenic Drivers

Other Oncogenic Drivers (1/2)

EPICS

For patients with *KRAS* G12C mutation-positive NSCLC, expert opinion is that these patients have disease that generally responds well

Other Oncogenic Drivers (2/2)

EPICS

In patients with *ALK*-rearranged NSCLC, most of the experts use alectinib or brigatinib as first-line therapy; one mentioned choosing

APTITUDE HEALTH®

EPICS

Congress Highlights

Small Cell Lung Cancer

First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)

Wermke M, et al. ASCO 2023, Abstract 8502

EPICS

STUDY POPULATION

> Pts with advanced, DLL3-positive SCLC, LCNEC, or epNEC

TUMOR RESPONSE (DOSES ≥90 µg/kg)

SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)

Karim NFA, et al. ASCO 2023, Abstract 8504

EPICS

STUDY POPULATION

> Pts with *SLFN11*-positive (IHC) SCLC and no progression after 4

PROGRESSION-FREE SURVIVAL

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer

Morgensztern D, et al. ASCO 2023, Abstract 3002

EPICS

STUDY POPULATION

- Pts with relapsed/refractory SCLC (1–3 prior lines of therapy)
- *SEZ6* positivity (≥25% tumor cells with 1+ staining intensity)

ANTITUMOR ACTIVITY (ALL PTS)



APTITUDE HEALTH®

EPICS

Key Insights

Small Cell Lung Cancer

Small Cell Lung Cancer

EPICS

Expert opinion is that DLL3 is a valid therapeutic target, as patients can have durable responses to DLL3-targeted agents, but similar to

APTITUDE HEALTH®

US 5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com